Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted pipeline therapeutics. The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects - The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) Overview 9 Therapeutics Development 10 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Stage of Development 10 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Therapy Area 11 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Indication 12 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Pipeline Products Glance 14 Late Stage Products 14 Early Stage Products 15 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Companies 16 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Products under Development by Universities/Institutes 21 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29 4SC AG 29 Acetylon Pharmaceuticals, Inc. 30 Chipscreen Biosciences Ltd 31 Curis, Inc. 32 GlaxoSmithKline Plc 33 HitGen LTD 34 Italfarmaco S.p.A. 35 MEI Pharma, Inc. 36 Merck & Co., Inc. 37 Rodin Therapeutics 38 Sigma-Tau S.p.A. 39 TetraLogic Pharmaceuticals 40 Yungjin Pharm. Co., Ltd. 41 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Drug Profiles 42 4SC-202 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ACY-738 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ACY-957 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 chidamide - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 CS-3158 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CUDC-907 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 givinostat - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 HG-3001 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Largazole - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 N-140 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 pracinostat - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 remetinostat - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 ST-3595 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 vorinostat - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 YPL-001 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Dormant Projects 78 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) - Featured News & Press Releases 81 Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 81 Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 81 May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 81 Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 82 Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 83 Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 83 Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 84 Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 84 Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 84 Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 85 Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 86 Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 88 Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 89 Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting 89 Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 89 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 91 Disclaimer 92
List of Tables
Number of Products under Development for, H1 2016 10 Number of Products under Development by Therapy Area, H1 2016 11 Number of Products under Development by Indication, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Development by Companies, H1 2016 (Contd..2) 19 Products under Development by Companies, H1 2016 (Contd..3) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Products under Investigation by Universities/Institutes, H1 2016 22 Assessment by Monotherapy/Combination Products, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 28 Pipeline by 4SC AG, H1 2016 29 Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 30 Pipeline by Chipscreen Biosciences Ltd, H1 2016 31 Pipeline by Curis, Inc., H1 2016 32 Pipeline by GlaxoSmithKline Plc, H1 2016 33 Pipeline by HitGen LTD, H1 2016 34 Pipeline by Italfarmaco S.p.A., H1 2016 35 Pipeline by MEI Pharma, Inc., H1 2016 36 Pipeline by Merck & Co., Inc., H1 2016 37 Pipeline by Rodin Therapeutics, H1 2016 38 Pipeline by Sigma-Tau S.p.A., H1 2016 39 Pipeline by TetraLogic Pharmaceuticals, H1 2016 40 Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 41 Dormant Projects, H1 2016 78 Dormant Projects (Contd..1), H1 2016 79 Dormant Projects (Contd..2), H1 2016 80
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
